Dr. Sharpless said the administration would continue its efforts to curb youth tobacco use and rein in prescription drug costs by increasing competition and advancing its generic drug and biosimilars programs.
“I am not planning any radical changes from what the FDA has been trying to accomplish,” Dr. Sharpless said. “I plan to maintain FDA’s current course of action in every area and proceed full speed ahead.”
Dr. Sharpless told attendees of the meeting that he will be releasing a more detailed explanation of his public health priorities in the coming weeks.
Dr. Sharpless is the former director of the National Cancer Institute.
More articles on leadership:
South Carolina hospital shootings spur other facilities to review safety plans
6 recent healthcare layoffs
Bon Secours St. Francis Health System to close South Carolina medical plaza, lay off 60
